Development of novel human antibody against malignant glioma-derived stem cell
| Project/Area Number |
25430166
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Shizuoka Cancer Center Research Institute |
|---|
Principal Investigator |
Akiyama Yasuto 静岡県立静岡がんセンター(研究所), その他部局等, その他 (70222552)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 抗体医薬 / がん性幹細胞 / 悪性グリオーマ / ヒト化マウス / ヒトモノクローナル抗体 |
|---|
| Outline of Final Research Achievements |
We aimed with developing human monoclonal antibody against YKL-40 protein, which is specifically expressed on malignant glioma-derived stem cell line established at Shizuoka Cancer Center, using humanized NOG-IL-4 transgenic (TG) mice. After immunization of recombinant human YKL-40 protein to humanized NOG-IL-4 TG mice and verification of antibody titer elevation, 7 anti-YKL-40 antibody-bearing single B cells out of ten million oflymphocytes were identified and sebsequently 4 specific antibody cDNAs were successfully cloned. Finally, 3 human recombinat monoclonal antibodies against YKL-40 protein were obtained using expi293 cells transduced with antibody genes consisting of VH and VL gene. These antibodies have still weak binding affinity for YKL-40 protein, therefore affinity maturation process will be needed using a phage display system.
|
Report
(4 results)
Research Products
(15 results)
-
-
[Journal Article] Immunologically augmented skin flap as a novel dendritic cell vaccine against head and neck cancer in a rat model.2015
Author(s)
Inoue K, Saegusa N, Omiya M, Ashizawa T, Miyata H, Komiyama M, Iizuka A, Kume A, Sugino T, Yamaguchi K, Kiyohara Y, Nakagawa M, Akiyama Y.
-
Journal Title
Cancer Sci
Volume: 106 (2)
Pages: 143-150
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
[Journal Article] YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.2014
Author(s)
Akiyama Y, Ashizawa T, Komiyama M, Miyata H, Oshita C, Omiya M, Iizuka A, Kume A, Sugino T, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K.
-
Journal Title
Oncology Rep.
Volume: 32 (1)
Pages: 159-166
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
[Journal Article] Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.2014
Author(s)
Ashizawa T, Akiyama Y, Miyata H, Iizuka A, Komiyama M, Kume A, Omiya M, Sugino T, Asai A, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K.
-
Journal Title
Int. J. Oncol.
Volume: 45 (1)
Pages: 411-418
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
